nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—HTR1E—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0236	0.0236	CbGpPWpGaD
Aripiprazole—HTR1E—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0188	0.0188	CbGpPWpGaD
Aripiprazole—DRD5—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0166	0.0166	CbGpPWpGaD
Aripiprazole—HTR1D—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.016	0.016	CbGpPWpGaD
Aripiprazole—HTR1B—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0157	0.0157	CbGpPWpGaD
Aripiprazole—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.0155	0.0155	CbGpPWpGaD
Aripiprazole—DRD4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0154	0.0154	CbGpPWpGaD
Aripiprazole—CHRM4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0152	0.0152	CbGpPWpGaD
Aripiprazole—HTR1E—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0143	0.0143	CbGpPWpGaD
Aripiprazole—DRD3—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0137	0.0137	CbGpPWpGaD
Aripiprazole—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0128	0.0128	CbGpPWpGaD
Aripiprazole—HTR7—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0128	0.0128	CbGpPWpGaD
Aripiprazole—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0127	0.0127	CbGpPWpGaD
Aripiprazole—DRD5—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0127	0.0127	CbGpPWpGaD
Aripiprazole—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0125	0.0125	CbGpPWpGaD
Aripiprazole—ADRA2B—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0124	0.0124	CbGpPWpGaD
Aripiprazole—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0123	0.0123	CbGpPWpGaD
Aripiprazole—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0121	0.0121	CbGpPWpGaD
Aripiprazole—HTR1A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.012	0.012	CbGpPWpGaD
Aripiprazole—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0117	0.0117	CbGpPWpGaD
Aripiprazole—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0116	0.0116	CbGpPWpGaD
Aripiprazole—ADRA2C—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0116	0.0116	CbGpPWpGaD
Aripiprazole—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0111	0.0111	CbGpPWpGaD
Aripiprazole—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0109	0.0109	CbGpPWpGaD
Aripiprazole—DRD2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0105	0.0105	CbGpPWpGaD
Aripiprazole—CHRM2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Aripiprazole—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00994	0.00994	CbGpPWpGaD
Aripiprazole—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00985	0.00985	CbGpPWpGaD
Aripiprazole—HTR6—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00978	0.00978	CbGpPWpGaD
Aripiprazole—HTR7—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00977	0.00977	CbGpPWpGaD
Aripiprazole—HTR1D—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0097	0.0097	CbGpPWpGaD
Aripiprazole—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00951	0.00951	CbGpPWpGaD
Aripiprazole—HTR1B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0095	0.0095	CbGpPWpGaD
Aripiprazole—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00946	0.00946	CbGpPWpGaD
Aripiprazole—ADRA2A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0094	0.0094	CbGpPWpGaD
Aripiprazole—DRD4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00935	0.00935	CbGpPWpGaD
Aripiprazole—CHRM4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00922	0.00922	CbGpPWpGaD
Aripiprazole—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0092	0.0092	CbGpPWpGaD
Aripiprazole—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00905	0.00905	CbGpPWpGaD
Aripiprazole—HTR2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00893	0.00893	CbGpPWpGaD
Aripiprazole—CHRM5—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00883	0.00883	CbGpPWpGaD
Aripiprazole—DRD1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00842	0.00842	CbGpPWpGaD
Aripiprazole—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00835	0.00835	CbGpPWpGaD
Aripiprazole—DRD3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00831	0.00831	CbGpPWpGaD
Aripiprazole—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00821	0.00821	CbGpPWpGaD
Aripiprazole—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00819	0.00819	CbGpPWpGaD
Aripiprazole—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00817	0.00817	CbGpPWpGaD
Aripiprazole—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00814	0.00814	CbGpPWpGaD
Aripiprazole—HTR1E—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00809	0.00809	CbGpPWpGaD
Aripiprazole—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00806	0.00806	CbGpPWpGaD
Aripiprazole—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00804	0.00804	CbGpPWpGaD
Aripiprazole—ADRB1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00757	0.00757	CbGpPWpGaD
Aripiprazole—ADRA2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0075	0.0075	CbGpPWpGaD
Aripiprazole—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00747	0.00747	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00735	0.00735	CbGpPWpGaD
Aripiprazole—HTR1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00724	0.00724	CbGpPWpGaD
Aripiprazole—HTR2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0072	0.0072	CbGpPWpGaD
Aripiprazole—DRD5—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00716	0.00716	CbGpPWpGaD
Aripiprazole—ADRA2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.007	0.007	CbGpPWpGaD
Aripiprazole—ADRA1B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00689	0.00689	CbGpPWpGaD
Aripiprazole—DRD5—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0065	0.0065	CbGpPWpGaD
Aripiprazole—DRD2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00636	0.00636	CbGpPWpGaD
Aripiprazole—HTR2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00625	0.00625	CbGpPWpGaD
Aripiprazole—HRH1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00624	0.00624	CbGpPWpGaD
Aripiprazole—CHRM1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00622	0.00622	CbGpPWpGaD
Aripiprazole—CHRM3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0062	0.0062	CbGpPWpGaD
Aripiprazole—CHRM2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00614	0.00614	CbGpPWpGaD
Aripiprazole—ADRA1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00612	0.00612	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00569	0.00569	CbGpPWpGaD
Aripiprazole—HTR6—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00553	0.00553	CbGpPWpGaD
Aripiprazole—HTR7—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00552	0.00552	CbGpPWpGaD
Aripiprazole—HTR1D—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00548	0.00548	CbGpPWpGaD
Aripiprazole—HTR1B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00537	0.00537	CbGpPWpGaD
Aripiprazole—DRD4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00528	0.00528	CbGpPWpGaD
Aripiprazole—CHRM4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00521	0.00521	CbGpPWpGaD
Aripiprazole—HTR2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00504	0.00504	CbGpPWpGaD
Aripiprazole—HTR6—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00502	0.00502	CbGpPWpGaD
Aripiprazole—HTR7—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00501	0.00501	CbGpPWpGaD
Aripiprazole—CHRM5—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00499	0.00499	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00498	0.00498	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00488	0.00488	CbGpPWpGaD
Aripiprazole—DRD4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0048	0.0048	CbGpPWpGaD
Aripiprazole—DRD1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00476	0.00476	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00473	0.00473	CbGpPWpGaD
Aripiprazole—DRD3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00469	0.00469	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00458	0.00458	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00453	0.00453	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—CXCL11—nasal cavity cancer	0.00434	0.00434	CbGpPWpGaD
Aripiprazole—DRD1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00432	0.00432	CbGpPWpGaD
Aripiprazole—ADRB1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00428	0.00428	CbGpPWpGaD
Aripiprazole—DRD3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00426	0.00426	CbGpPWpGaD
Aripiprazole—ADRA2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00424	0.00424	CbGpPWpGaD
Aripiprazole—HTR1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00409	0.00409	CbGpPWpGaD
Aripiprazole—HTR2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00407	0.00407	CbGpPWpGaD
Aripiprazole—ADRA2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00396	0.00396	CbGpPWpGaD
Aripiprazole—ADRA1B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0039	0.0039	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00388	0.00388	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00385	0.00385	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—CXCL11—nasal cavity cancer	0.00384	0.00384	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00371	0.00371	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0037	0.0037	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00359	0.00359	CbGpPWpGaD
Aripiprazole—DRD2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00359	0.00359	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00354	0.00354	CbGpPWpGaD
Aripiprazole—HTR2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00353	0.00353	CbGpPWpGaD
Aripiprazole—HRH1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00353	0.00353	CbGpPWpGaD
Aripiprazole—CHRM1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00351	0.00351	CbGpPWpGaD
Aripiprazole—CHRM3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0035	0.0035	CbGpPWpGaD
Aripiprazole—CHRM2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00347	0.00347	CbGpPWpGaD
Aripiprazole—ADRA1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00346	0.00346	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00326	0.00326	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00321	0.00321	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00321	0.00321	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00319	0.00319	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00315	0.00315	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00314	0.00314	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—CXCL11—nasal cavity cancer	0.00296	0.00296	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—CXCL11—nasal cavity cancer	0.00296	0.00296	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—CXCL11—nasal cavity cancer	0.00294	0.00294	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00292	0.00292	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00288	0.00288	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00283	0.00283	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—CXCL11—nasal cavity cancer	0.0028	0.0028	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00271	0.00271	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—CXCL11—nasal cavity cancer	0.00268	0.00268	CbGpPWpGaD
Aripiprazole—HTR1E—Signaling Pathways—FRS2—nasal cavity cancer	0.00256	0.00256	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00255	0.00255	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00252	0.00252	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00229	0.00229	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00227	0.00227	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—FRS2—nasal cavity cancer	0.00226	0.00226	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00219	0.00219	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00218	0.00218	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00212	0.00212	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00209	0.00209	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00193	0.00193	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.0019	0.0019	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00189	0.00189	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00189	0.00189	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00188	0.00188	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00186	0.00186	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00186	0.00186	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—FRS2—nasal cavity cancer	0.00175	0.00175	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—FRS2—nasal cavity cancer	0.00175	0.00175	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—FRS2—nasal cavity cancer	0.00173	0.00173	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00172	0.00172	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—FRS2—nasal cavity cancer	0.0017	0.0017	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—FRS2—nasal cavity cancer	0.00167	0.00167	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—FRS2—nasal cavity cancer	0.00165	0.00165	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—FRS2—nasal cavity cancer	0.00159	0.00159	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—FRS2—nasal cavity cancer	0.00158	0.00158	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—FRS2—nasal cavity cancer	0.0015	0.0015	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—FRS2—nasal cavity cancer	0.00148	0.00148	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—FRS2—nasal cavity cancer	0.00135	0.00135	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—FRS2—nasal cavity cancer	0.00134	0.00134	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00125	0.00125	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—FRS2—nasal cavity cancer	0.00114	0.00114	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00112	0.00112	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—FRS2—nasal cavity cancer	0.00111	0.00111	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—FRS2—nasal cavity cancer	0.00111	0.00111	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—FRS2—nasal cavity cancer	0.00111	0.00111	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—FRS2—nasal cavity cancer	0.0011	0.0011	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00109	0.00109	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00102	0.00102	CbGpPWpGaD
